Symbols / NAGE Stock $4.93 +4.23% Niagen Bioscience, Inc.

Healthcare • Biotechnology • United States • NCM
NAGE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert N. Fried
Exch · Country NCM · United States
Market Cap 394.80M
Enterprise Value 333.80M
Income 17.38M
Sales 129.42M
FCF (ttm) 4.88M
Book/sh 0.96
Cash/sh 0.81
Employees 117
Insider 10d —
IPO Jun 25, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 24.65
Forward P/E 15.41
PEG —
P/S 3.05
P/B 5.15
P/C —
EV/EBITDA 22.13
EV/Sales 2.58
Quick Ratio 3.73
Current Ratio 4.86
Debt/Eq 3.68
LT Debt/Eq —
EPS (ttm) 0.20
EPS next Y 0.32
EPS Growth -41.60%
Revenue Growth 16.20%
EPS Gr Q/Q -42.40%
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-04
ROA 10.23%
ROE 28.35%
ROIC —
Gross Margin 64.28%
Oper. Margin 6.21%
Profit Margin 13.43%
Shs Outstand 80.08M
Shs Float 52.89M
Insider Own 33.89%
Instit Own 41.89%
Short Float 10.28%
Short Ratio 5.72
Short Interest 5.45M
52W High 14.69
vs 52W High -66.44%
52W Low 4.16
vs 52W Low 18.51%
Beta 2.23
Impl. Vol. 1.56%
Rel Volume 0.41
Avg Volume 1.18M
Volume 489.39K
Target (mean) $13.60
Tgt Median $13.00
Tgt Low $12.00
Tgt High $18.00
# Analysts 5
Recom Strong_buy
Prev Close $4.73
Price $4.93
Change 4.23%
About

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.60
Mean price target
2. Current target
$4.93
Latest analyst target
3. DCF / Fair value
$1.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.93
Low
$12.00
High
$18.00
Mean
$13.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 main Canaccord Genuity Buy → Buy $13
2026-03-05 main Canaccord Genuity Buy → Buy $13
2025-11-05 main Canaccord Genuity Buy → Buy $14
2025-08-11 main HC Wainwright & Co. Buy → Buy $12
2025-06-10 main Canaccord Genuity Buy → Buy $16
2025-06-06 main Roth Capital Buy → Buy $23
2025-05-27 init Canaccord Genuity — → Buy $13
2025-04-08 reit HC Wainwright & Co. Buy → Buy $11
2025-03-31 reit HC Wainwright & Co. Buy → Buy $11
2025-03-17 reit HC Wainwright & Co. Buy → Buy $11
2025-03-10 main HC Wainwright & Co. Buy → Buy $11
2025-03-05 main Ladenburg Thalmann Buy → Buy $8
2024-11-06 main Roth MKM Buy → Buy $8
2024-11-04 main HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest NAGE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 PAMIR OZAN Chief Financial Officer — 6,685 $6.81 $45,616
2025-04-09 FRIED ROBERT N. Chief Executive Officer — 66,667 $3.30 $220,001
2025-03-07 LOPEZ CARLOS LUIS General Counsel — 273 $7.86 $2,146
2024-12-13 JAKSCH FRANK LOUIS JR Director — 37,161 $6.19 $229,956
2024-12-13 JAKSCH FRANK LOUIS JR Director — 50,001 $3.66 $183,004
2024-11-22 PAMIR OZAN Chief Financial Officer — 2,907 $7.36 $21,397
2024-08-23 PATRICK KRISTIN Director — 23,000 $3.57 $82,110
2024-08-23 PATRICK KRISTIN Director — 23,000 $1.64 $38,320
2024-08-20 LI KA SHING Beneficial Owner of more than 10% of a Class of Security — 11,408,715 $3.34 $38,105,108
2024-08-20 CHAU HOI SHUEN SOLINA HOLLY Beneficial Owner of more than 10% of a Class of Security — 11,408,715 $3.34 $38,105,108
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
129.42
+29.95%
99.60
+19.18%
83.57
+15.99%
72.05
Operating Revenue
129.42
+29.95%
99.60
+19.18%
83.57
+15.99%
72.05
Cost Of Revenue
46.23
+21.63%
38.01
+15.92%
32.79
+12.09%
29.25
Reconciled Cost Of Revenue
46.23
+21.63%
38.01
+15.92%
32.79
+12.09%
29.25
Gross Profit
83.19
+35.08%
61.59
+21.28%
50.78
+18.65%
42.80
Operating Expense
68.89
+27.91%
53.86
-4.47%
56.38
-8.21%
61.42
Research And Development
6.33
+5.22%
6.02
+21.34%
4.96
+2.74%
4.83
Selling General And Administration
62.56
+30.76%
47.84
-6.96%
51.42
-9.15%
56.60
Selling And Marketing Expense
35.51
+20.49%
29.47
+11.46%
26.44
-6.62%
28.31
General And Administrative Expense
27.06
+47.25%
18.38
-26.45%
24.98
-11.68%
28.29
Other Gand A
27.06
+47.25%
18.38
-26.45%
24.98
-11.68%
28.29
Total Expenses
115.13
+25.31%
91.87
+3.03%
89.17
-1.66%
90.68
Operating Income
14.30
+85.04%
7.73
+237.99%
-5.60
+69.94%
-18.63
Total Operating Income As Reported
16.28
+110.70%
7.73
+237.99%
-5.60
+69.94%
-18.63
EBITDA
15.75
+70.97%
9.21
+336.52%
-3.89
+76.74%
-16.74
Normalized EBITDA
13.76
+49.44%
9.21
+336.52%
-3.89
+76.74%
-16.74
Reconciled Depreciation
1.45
-2.29%
1.48
-12.96%
1.71
-9.50%
1.88
EBIT
14.30
+85.04%
7.73
+237.99%
-5.60
+69.94%
-18.63
Total Unusual Items
1.98
0.00
—
—
Total Unusual Items Excluding Goodwill
1.98
0.00
—
—
Special Income Charges
1.98
0.00
—
—
Other Special Charges
-1.98
—
—
—
Net Income
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Pretax Income
18.19
+105.44%
8.86
+279.32%
-4.94
+70.15%
-16.54
Net Non Operating Interest Income Expense
2.13
+88.40%
1.13
+70.80%
0.66
+21933.33%
0.00
Net Interest Income
2.13
+88.40%
1.13
+70.80%
0.66
+21933.33%
0.00
Interest Income Non Operating
2.13
+88.40%
1.13
+70.80%
0.66
+21933.33%
0.00
Interest Income
2.13
+88.40%
1.13
+70.80%
0.66
+21933.33%
0.00
Other Income Expense
1.77
—
—
2.08
Other Non Operating Income Expenses
-0.21
—
—
2.08
Tax Provision
0.81
+165.57%
0.30
0.00
—
Tax Rate For Calcs
0.00
+30.65%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.09
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Net Income From Continuing Operation Net Minority Interest
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Net Income From Continuing And Discontinued Operation
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Net Income Continuous Operations
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Normalized Income
15.49
+81.15%
8.55
+273.15%
-4.94
+70.15%
-16.54
Net Income Common Stockholders
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Diluted EPS
0.20
+81.82%
0.11
+257.14%
-0.07
+70.83%
-0.24
Basic EPS
0.22
+100.00%
0.11
+257.14%
-0.07
+70.83%
-0.24
Basic Average Shares
79.18
+4.28%
75.93
+1.26%
74.98
+7.54%
69.73
Diluted Average Shares
85.44
+9.36%
78.12
+4.19%
74.98
+7.54%
69.73
Diluted NI Availto Com Stockholders
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Total Other Finance Cost
—
—
—
-0.00
Line Item Trend 2023-12-31
Total Assets
54.96
Current Assets
49.53
Cash Cash Equivalents And Short Term Investments
27.17
Cash And Cash Equivalents
27.17
Cash Financial
—
Receivables
5.23
Accounts Receivable
5.23
Gross Accounts Receivable
5.30
Allowance For Doubtful Accounts Receivable
-0.07
Inventory
14.53
Raw Materials
4.48
Work In Process
3.54
Finished Goods
5.96
Prepaid Assets
—
Restricted Cash
0.15
Assets Held For Sale Current
—
Other Current Assets
2.45
Total Non Current Assets
5.43
Net PPE
4.54
Gross PPE
9.95
Accumulated Depreciation
-5.41
Properties
0.00
Machinery Furniture Equipment
0.99
Construction In Progress
0.01
Other Properties
6.81
Leases
2.15
Goodwill And Other Intangible Assets
0.51
Other Intangible Assets
0.51
Other Non Current Assets
0.38
Total Liabilities Net Minority Interest
26.51
Current Liabilities
20.62
Payables And Accrued Expenses
19.73
Payables
10.23
Accounts Payable
10.23
Current Accrued Expenses
9.49
Current Debt And Capital Lease Obligation
0.70
Current Capital Lease Obligation
0.70
Current Deferred Liabilities
0.20
Current Deferred Revenue
0.20
Total Non Current Liabilities Net Minority Interest
5.89
Long Term Debt And Capital Lease Obligation
2.58
Long Term Capital Lease Obligation
2.58
Non Current Deferred Liabilities
3.31
Non Current Deferred Revenue
3.31
Stockholders Equity
28.46
Common Stock Equity
28.46
Capital Stock
0.07
Common Stock
0.07
Share Issued
74.98
Ordinary Shares Number
74.98
Treasury Shares Number
0.00
Additional Paid In Capital
218.84
Retained Earnings
-190.46
Gains Losses Not Affecting Retained Earnings
-0.00
Total Equity Gross Minority Interest
28.46
Total Capitalization
28.46
Working Capital
28.91
Invested Capital
28.46
Total Debt
3.28
Capital Lease Obligations
3.28
Net Tangible Assets
27.95
Tangible Book Value
27.95
Foreign Currency Translation Adjustments
-0.00
Other Inventories
0.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
13.50
+11.52%
12.11
+70.14%
7.12
+147.14%
-15.10
Cash Flow From Continuing Operating Activities
13.50
+11.52%
12.11
+70.14%
7.12
+147.14%
-15.10
Net Income From Continuing Operations
17.38
+103.30%
8.55
+273.15%
-4.94
+70.15%
-16.54
Depreciation Amortization Depletion
1.45
-2.29%
1.48
-12.96%
1.71
-9.50%
1.88
Depreciation
1.28
-4.20%
1.33
-13.83%
1.55
-8.89%
1.70
Amortization Cash Flow
0.17
+14.57%
0.15
-4.43%
0.16
-15.05%
0.19
Depreciation And Amortization
1.45
-2.29%
1.48
-12.96%
1.71
-9.50%
1.88
Amortization Of Intangibles
0.17
+14.57%
0.15
-4.43%
0.16
-15.05%
0.19
Other Non Cash Items
-1.95
+44.61%
-3.52
-23593.33%
0.01
+106.33%
-0.24
Stock Based Compensation
6.07
+65.95%
3.66
-23.05%
4.75
-17.22%
5.74
Provisionand Write Offof Assets
-1.22
+3.03%
-1.25
-230.19%
0.96
+1430.16%
0.06
Asset Impairment Charge
—
0.00
-100.00%
0.00
0.00
Operating Gains Losses
0.00
+121.05%
-0.02
-280.00%
-0.01
-171.43%
0.01
Gain Loss On Sale Of PPE
0.00
+121.05%
-0.02
-280.00%
-0.01
-171.43%
0.01
Change In Working Capital
-8.23
-355.83%
3.22
-30.40%
4.62
+176.85%
-6.01
Change In Receivables
-0.76
+40.89%
-1.28
-156.72%
2.25
+167.94%
-3.32
Changes In Account Receivables
-0.76
+40.89%
-1.28
-156.72%
2.25
+167.94%
-3.32
Change In Inventory
-11.63
-318.17%
5.33
+3408.55%
0.15
+114.13%
-1.08
Change In Prepaid Assets
1.12
+2591.11%
-0.04
-107.13%
0.63
+172.36%
-0.87
Change In Payables And Accrued Expense
4.11
+2857.55%
0.14
-94.87%
2.71
+2318.75%
0.11
Change In Accrued Expense
1.84
+52.65%
1.21
-44.06%
2.16
+151.87%
0.86
Change In Payable
2.27
+312.75%
-1.07
-292.95%
0.55
+174.33%
-0.74
Change In Account Payable
2.27
+312.75%
-1.07
-292.95%
0.55
+174.33%
-0.74
Change In Other Working Capital
-0.12
+61.39%
-0.32
+47.85%
-0.61
-53.03%
-0.40
Change In Other Current Liabilities
-0.95
-54.31%
-0.61
-18.50%
-0.52
-12.10%
-0.46
Investing Cash Flow
-0.29
-104.20%
-0.14
+0.00%
-0.14
+57.19%
-0.33
Cash Flow From Continuing Investing Activities
-0.29
-104.20%
-0.14
+0.00%
-0.14
+57.19%
-0.33
Net PPE Purchase And Sale
-0.29
-104.20%
-0.14
+0.00%
-0.14
+57.19%
-0.33
Purchase Of PPE
-0.29
-79.14%
-0.16
-10.14%
-0.15
+55.69%
-0.33
Sale Of PPE
0.00
-100.00%
0.02
+300.00%
0.01
0.00
Capital Expenditure
-0.29
-79.14%
-0.16
-10.14%
-0.15
+55.69%
-0.33
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Financing Cash Flow
6.92
+28.81%
5.37
+6065.56%
-0.09
-101.18%
7.65
Cash Flow From Continuing Financing Activities
6.92
+28.81%
5.37
+6065.56%
-0.09
-101.18%
7.65
Net Issuance Payments Of Debt
-0.01
-9.09%
-0.01
+26.67%
-0.01
+6.25%
-0.02
Repayment Of Debt
-0.01
-9.09%
-0.01
+26.67%
-0.01
+6.25%
-0.02
Long Term Debt Payments
-0.01
-9.09%
-0.01
+26.67%
-0.01
+6.25%
-0.02
Net Long Term Debt Issuance
-0.01
-9.09%
-0.01
+26.67%
-0.01
+6.25%
-0.02
Net Common Stock Issuance
-0.25
0.00
0.00
-100.00%
7.75
Common Stock Payments
-0.25
0.00
—
—
Repurchase Of Capital Stock
-0.25
0.00
—
—
Proceeds From Stock Option Exercised
7.25
+33.39%
5.43
0.00
0.00
Net Other Financing Charges
-0.07
-28.85%
-0.05
+30.67%
-0.07
+2.60%
-0.08
Changes In Cash
20.13
+16.11%
17.34
+151.82%
6.88
+188.51%
-7.78
Beginning Cash Position
44.66
+63.44%
27.32
+33.68%
20.44
-27.56%
28.22
End Cash Position
64.79
+45.07%
44.66
+63.44%
27.32
+33.68%
20.44
Free Cash Flow
13.21
+10.60%
11.95
+71.42%
6.97
+145.16%
-15.43
Interest Paid Supplemental Data
0.00
+0.00%
0.00
-50.00%
0.00
+100.00%
0.00
Common Stock Issuance
—
—
0.00
-100.00%
7.75
Issuance Of Capital Stock
—
—
0.00
-100.00%
7.75
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category